Bromperidol, a new potent neuroleptic of the butyrophenone series. A comparison of the effects of bromperidol and haloperidol in intracranial self-stimulation.
A. Wauquier, Niemegeers Cj
Abstract
A. Wauquier, Niemegeers Cj
Abstract
Bromperidol, a new potent and long-acting neuroleptic of the butyrophenone series, and haloperidol were injected s.c. at the doses 0.01, 0.02, 0.04 and 0.08 mg/kg, in rats implanted with electrodes in the lateral hypothalamic region of the medial forebrain bundle. A dose-related response inhibition was found with both compounds and the graphically estimated ED50 value was 0.041 mg/kg for bromperidol and 0.047 mg/kg for haloperidol. These data are in complete agreement with our previous findings that bromperidol is a new potent and specific neuroleptic.
OpenAlex reports 2 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Bromperidol, a new potent and long-acting neuroleptic of the butyrophenone series, and haloperidol were injected s.c. at the doses 0.01, 0.02, 0.04 and 0.08 mg/kg, in rats implanted with electrodes in the lateral hypothalamic region of the medial forebrain bundle. A dose-related response inhibition was found with both compounds and the graphically estimated ED50 value was 0.041 mg/kg for bromperidol and 0.047 mg/kg for haloperidol. These data are in complete agreement with our previous findings that bromperidol is a new potent and specific neuroleptic.
Key concepts: Butyrophenone, Haloperidol, ED50, Pharmacology, Medial forebrain bundle, Chemistry, Stimulation, Internal medicine